SinoMab BioScience Limited is a Hong Kong-based biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of therapeutics for immunological diseases. With a goal to become a leading global biopharmaceutical company, SinoMab is dedicated to the development of novel drugs. One of their flagship products is SM03, a potential global first-in-target monoclonal antibody (mAb) against CD22 for the treatment of rheumatoid arthritis.

Currently, it is in Phase III clinical trials in China and has been recognized as a significant special project of Significant New Drugs Development of the Thirteenth Five-Year Plan Period. In addition to SM03, SinoMab also has a diverse product pipeline that includes core products such as an anti-CD22 first-in-target NCE drug candidate, BTK inhibitor, humanized anti-IL17BR, and humanized anti-CD20 and anti-CD22. SinoMab's commitment to innovation and expertise in biopharmaceuticals positions them as a key player in the industry.

For more information about their products and services, you can visit their website or contact them directly through their office in Hong Kong